Rena Therapeutics was established in January 2015 as the venture company from Tokyo Medical and Dental University to promote and facilitate drug discovery research and development of next-generation nucleic acid therapeutics.
While nucleic acid therapeutics has the advantage of targeting diseases that cannot be targeted with conventional drugs, there are challenges such as delivery, and only a few nucleic acid therapeutics has been approved.
Heteroduplex oligonucleotide (HDO), our core technology, is a new breakthrough in nucleic acid therapeutics development because it has a high probability to realize delivery to disease sites other than the liver by binding various ligands. By putting this technology to practical use, we will continue to take on the challenge of responding to unmet medical needs, including cancer and intractable diseases, with the aim of delivering nucleic acid therapeutics to patients as quickly as possible.
Representative Director and CEO Shuichi Toriya